Antiretroviral News and Research

RSS

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013

New NIH guidelines for managing opportunistic infections in children with HIV

Sharon Nachman, MD, a pediatric HIV and infectious diseases specialist at Stony Brook Children's Hospital, is a co-author of new National Institutes of Health (NIH)-issued guidelines for the prevention, treatment and management of opportunistic infections in HIV-exposed and HIV-infected children. The 2013 guidelines shed light on the most effective way to treat dangerous and deadly infections such as pneumonia or tuberculosis that can strike immunosuppressed pediatric HIV patients.

27 Nov 2013

European research project examines toxicity factor to fight AIDS

December 1st is the annual World AIDS Day, a perfect opportunity to look at how medical research is progressing to fight the disease.

27 Nov 2013

WHO releases new treatment guidelines for children suffering severe acute malnutrition

WHO today released new treatment guidelines for the almost 20 million children under-five worldwide who have severe acute malnutrition.

27 Nov 2013

MSF launches film series to counterbalance rhetoric presenting the fight against HIV/AIDS as almost won

The fight against HIV/AIDS has been hailed as one of the most successful public health projects in human history, but teams from the international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) see the revolution as unfulfilled for millions of people excluded from treatment.

26 Nov 2013

HIV patients face higher risk of virologic failure than previously thought

People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold, according to a study by Claudie Laprise at the University of Montreal's Department of Social and Preventative Medicine.

26 Nov 2013

Biocon receives regulatory approval for biosimilar product, trastuzumab

Mylan Inc. today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product.

26 Nov 2013

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

New bill offers hope to HIV patients on transplant waiting lists

A bill scheduled to be signed into law today by President Obama reverses the longtime ban on letting HIV-infected people donate their organs for transplantation after death, a move that offers hope to thousands of HIV patients on transplant waiting lists.

22 Nov 2013

New documentary reveals how antiretroviral therapy transformed lives of HIV people in Africa

A new documentary produced by the University of East Anglia reveals how the lives of people with HIV in Africa have been transformed by antiretroviral therapy and highlights the crucial need for continued funding of the lifesaving treatment.

22 Nov 2013

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.

18 Nov 2013

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

15 Nov 2013

Mylan Pharmaceuticals launches Rabeprazole Sodium Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg.

11 Nov 2013

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

Since the onset of the AIDS pandemic more than three decades ago, researchers from the lab and physicians in the clinic have been working toward one shared goal: an AIDS-free world. This week, a conference hosted by the journals Cell and The Lancet brought leading researchers and clinicians together to discuss recent findings that could bring hope to the estimated 35 million people world-wide who live with HIV.

7 Nov 2013

Mylan's revenues decrease 2% to $1.77B in third quarter 2013

Mylan Inc. today announced its financial results for the three and nine months ended September 30, 2013.

31 Oct 2013

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

HIV infection, not antiretroviral therapy (ART), is associated with risk for atherosclerosis in patients with no history of smoking, particularly those infected for eight years or more.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Potentially active forms of HIV hiding in infected immune T cells may be 60-fold greater, say experts

Just when some scientists were becoming more hopeful about finding a strategy to outwit HIV's ability to resist, evade and otherwise survive efforts to rid it from the body, another hurdle has emerged to foil their plans, new research from Johns Hopkins shows.

25 Oct 2013

HIV-positive patients with high CD4 cell counts are not at increased risk for heart attacks

Patients who are HIV-positive and have high CD4 cell counts - or have a high number of white blood cells that fight infections - aren't at an increased risk for heart attacks compared to patients who are HIV-negative, according to a Kaiser Permanente study that appears in the current online issue of the Journal of Acquired Immune Deficiency Syndromes.

25 Oct 2013

Full and early treatment may cure babies with HIV

A report published in The New England Journal of Medicine provides confirmation of what researchers say is the first case of HIV remission in a child born with the virus.

24 Oct 2013

Antiretroviral News and Research

Scientists design small synthetic molecules capable of blocking AIDS virus replication

New NIH guidelines for managing opportunistic infections in children with HIV

European research project examines toxicity factor to fight AIDS

WHO releases new treatment guidelines for children suffering severe acute malnutrition

MSF launches film series to counterbalance rhetoric presenting the fight against HIV/AIDS as almost won

HIV patients face higher risk of virologic failure than previously thought

Biocon receives regulatory approval for biosimilar product, trastuzumab

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

New bill offers hope to HIV patients on transplant waiting lists

New documentary reveals how antiretroviral therapy transformed lives of HIV people in Africa

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Mylan Pharmaceuticals launches Rabeprazole Sodium Delayed-release Tablets

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

Mylan's revenues decrease 2% to $1.77B in third quarter 2013

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Potentially active forms of HIV hiding in infected immune T cells may be 60-fold greater, say experts

HIV-positive patients with high CD4 cell counts are not at increased risk for heart attacks

Full and early treatment may cure babies with HIV

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News